Christopher Missling - Mar 24, 2025 Form 4 Insider Report for ANAVEX LIFE SCIENCES CORP. (AVXL)

Role: President and CEO, Director
Signature: /s/Christopher Missling
Stock symbol: AVXL
Transactions as of: Mar 24, 2025
Transactions value $: -$2,260,446
Form type: 4
Date filed: 3/26/2025, 09:30 PM
Previous filing: Jan 17, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AVXL	Common Stock	Options Exercise	$460K	+500K	+39.99%	$0.92	1.75M	Mar 24, 2025	Direct
transaction	AVXL	Common Stock	Tax liability	-$2.72M	-282K	-16.14%	$9.63	1.47M	Mar 24, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVXL	Stock Option (Right to Buy)	Options Exercise	$0	-500K	-100%	$0.00	0	Mar 24, 2025	Common Stock	500K	$0.92	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a "net exercise" of outstanding stock options, which options were scheduled to expire on April 2, 2025. The reporting person received 217,503 shares of common stock on net exercise of an option to purchase 500,000 shares of common stock. The Company withheld 282,497 shares of common stock underlying the option as consideration for the exercise price and tax withholdings, using the average of the high and low sales price on March 24, 2025 of $9.63, pursuant to the terms of the Company's 2007 Stock Option Plan.

Content

Represents a "net exercise" of outstanding stock options, which options were scheduled to expire on April 2, 2025. The reporting person received 217,503 shares of common stock on net exercise of an option to purchase 500,000 shares of common stock. The Company withheld 282,497 shares of common stock underlying the option as consideration for the exercise price and tax withholdings, using the average of the high and low sales price on March 24, 2025 of $9.63, pursuant to the terms of the Company's 2007 Stock Option Plan.